Renaud VAILLANT

Renaud VAILLANT is an experienced executive and entrepreneur in the biotechnology industry, currently serving as the Founder & President of Alaya.bio.14 Here's an overview of his background and current roles:

Professional Experience

Current Positions:

• Founder & President at Alaya.bio (since July 2022)1
• President at HONING BIOSCIENCES (since July 2022)1
• Managing Director at Deep Blue Consulting (since July 2006)1
• Co-founder & strategic advisor at Mooncard (since February 2016)1

Previous Roles:

• VP Business Development & Managing Director of Ixaka France (June 2020 - November 2021)1
• CEO & Board Member at THERAVECTYS (September 2010 - October 2015)1

Expertise and Focus

Renaud VAILLANT is passionate about innovation, disruptive technologies, and patient outcomes in the biotechnology sector.1 His expertise includes:

• Guiding therapeutic products from inception to proof-of-concept and clinical trials
• Cross-sector knowledge in various therapeutic areas (infectious diseases, oncology, genetic diseases)
• Corporate strategy and deal-making
• Business development and financial expertise in biotechnology

Current Work at Alaya.bio

At Alaya.bio, VAILLANT is leading the development of a novel polymeric delivery platform designed to precisely target and reprogram cells in situ.2 The company's focus is on simplifying the development, manufacturing, and administration of CAR-T cell therapies.2

Education

Renaud VAILLANT received his education from Ecole centrale de Paris.1

Recent Developments

In July 2024, Alaya.bio entered into a collaboration agreement with Nona Biosciences to advance CAR-T cell therapy.23 This partnership aims to combine Nona's antibody discovery platform with Alaya.bio's polymeric delivery system to develop new CAR-T product candidates.2

Renaud VAILLANT's leadership and extensive experience in the biotechnology industry position him as a key figure in the development of innovative cell therapies and drug delivery systems.